{"id":387563,"date":"2020-11-24T08:03:36","date_gmt":"2020-11-24T13:03:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387563"},"modified":"2020-11-24T08:03:36","modified_gmt":"2020-11-24T13:03:36","slug":"kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","title":{"rendered":"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">HAMILTON, Bermuda, Nov.  24, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Gwo3BJUjEvNiPBBt8UKmIHrXkFKaLLHnDE4dk5fmDnDqjNqMjUglVB4P8dYpAJFAT9tJJao7KKAO647rNtaKLUwi55-RtuKA_F2rbeT0p-U=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Kiniksa Pharmaceuticals, Ltd.<\/a> (Nasdaq: KNSA) announced today that it will present at\u00a0the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1<sup>st<\/sup>, 2020 at 8:50 a.m. Eastern Time.<\/p>\n<p>A live webcast of Kiniksa\u2019s presentation will be accessible through the Investors &amp; Media section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FSEeIRdgbTCGuQrx4rk31PF6hDNQ-xJ7QMq8AfQRvWU54mI-pnL3VWwdZggmsK60qrRgOWDKaLOlkPjPBW5EPw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.kiniksa.com<\/a>. A replay of the webcast will be available on Kiniksa\u2019s website for 14 days following the conference.<\/p>\n<p>\n        <strong>About Kiniksa<\/strong><br \/>\n        <br \/>Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa\u2019s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FSEeIRdgbTCGuQrx4rk31Oyv6BHMMxlvYyAvKnQQ-KKSJVAaq4WIyeBf-xvSeUIWlDQs2HOG-INVDyUIOzg8t_IP904ayIHbcjzwoYXjiYBQ-S9y0aIgSPRnIyztp49P23rkadsRJ0A-yNgpCcElw7eHXNg-ullLib-ZED5qFyLaZQmnO2RitxnhyjJnMibavxpqKdSwBrgj8M3EJX4xHjSM6-HwILLu-Fmh9-z326GU4iC-gjxzGUCd2ayQ5czkJbgi2Otm7iu8uOGieam1khX5dgvqM-92M91oxiBpEIjv0SmZa62m8p_KMMqa85HeI0y7XlGEAPS7F-KKJ1na_DWotTa1esX99rLHtFgG0irHl6pCy97yCX0FAp6i7aPkbUs4X5DgWURxqMYjH93vTZQ13r-qO11IJ9llwwkvihktsAe-mZx6e9B3oDKY55_4HdHCGqdvDk6J4pyimY8wkuT2xXPUab43pv1GTjQE7uYAKSsH4cwpV2pZy-dvOIM2s3oDRAOPjpnAgkd0nnZ_ARS1FrzUoFnj57s4hx2_5sUPCq_JXXgqTS_GL-eQU8p7RlvfjtSP7_YmprSZ6bqzncGSLYXfwBaQavb9qSWtxa4mg2RCnGaC-zL5Kq5UEzzRZAluGeONP0ymOVjSjcpZFyC4ZgGKJ4yHx7xynZSHNKQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.kiniksa.com<\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong><br \/>\n              <em>Every Second Counts!\u2122<\/em><br \/>\n            <\/strong><\/p>\n<p>            <strong>Kiniksa Investor and Media Contact<\/strong><br \/>\n            <br \/>Mark Ragosa<br \/>(781) 430-8289<br \/><a href=\"mailto:mragosa@kiniksa.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mragosa@kiniksa.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5c8181bf-05e7-4e5d-80c8-565069c22135\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at\u00a0the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st, 2020 at 8:50 a.m. Eastern Time. A live webcast of Kiniksa\u2019s presentation will be accessible through the Investors &amp; Media section of the company\u2019s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa\u2019s website for 14 days following the conference. About Kiniksa Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa\u2019s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387563","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at\u00a0the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st, 2020 at 8:50 a.m. Eastern Time. A live webcast of Kiniksa\u2019s presentation will be accessible through the Investors &amp; Media section of the company\u2019s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa\u2019s website for 14 days following the conference. About Kiniksa Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa\u2019s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved &hellip; Continue reading &quot;Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T13:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference\",\"datePublished\":\"2020-11-24T13:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"wordCount\":178,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"name\":\"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=\",\"datePublished\":\"2020-11-24T13:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","og_description":"HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at\u00a0the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st, 2020 at 8:50 a.m. Eastern Time. A live webcast of Kiniksa\u2019s presentation will be accessible through the Investors &amp; Media section of the company\u2019s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa\u2019s website for 14 days following the conference. About Kiniksa Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa\u2019s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved &hellip; Continue reading \"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T13:03:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference","datePublished":"2020-11-24T13:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/"},"wordCount":178,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","name":"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=","datePublished":"2020-11-24T13:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDk1MiMzODQwNTcwIzIwOTc3ODY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kiniksa-pharmaceuticals-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387563"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387563\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}